- Home
- EPC vs DNTH Comparison
EPC vs DNTH Comparison
Compare EPC & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPC
- DNTH
- Stock Information
- Founded
- EPC 1999
- DNTH 2015
- Country
- EPC United States
- DNTH United States
- Employees
- EPC N/A
- DNTH N/A
- Industry
- EPC Package Goods/Cosmetics
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- EPC Consumer Discretionary
- DNTH Health Care
- Exchange
- EPC Nasdaq
- DNTH Nasdaq
- Market Cap
- EPC 1.4B
- DNTH 1.5B
- IPO Year
- EPC 2000
- DNTH N/A
- Fundamental
- Price
- EPC $20.25
- DNTH $34.50
- Analyst Decision
- EPC Buy
- DNTH Strong Buy
- Analyst Count
- EPC 7
- DNTH 10
- Target Price
- EPC $28.29
- DNTH $66.38
- AVG Volume (30 Days)
- EPC 763.5K
- DNTH 947.1K
- Earning Date
- EPC 11-06-2025
- DNTH 11-06-2025
- Dividend Yield
- EPC 2.96%
- DNTH N/A
- EPS Growth
- EPC N/A
- DNTH N/A
- EPS
- EPC 1.34
- DNTH N/A
- Revenue
- EPC $2,203,900,000.00
- DNTH $4,854,000.00
- Revenue This Year
- EPC N/A
- DNTH N/A
- Revenue Next Year
- EPC $2.32
- DNTH N/A
- P/E Ratio
- EPC $15.12
- DNTH N/A
- Revenue Growth
- EPC N/A
- DNTH 17.87
- 52 Week Low
- EPC $19.13
- DNTH $13.37
- 52 Week High
- EPC $38.45
- DNTH $40.16
- Technical
- Relative Strength Index (RSI)
- EPC 39.91
- DNTH 50.57
- Support Level
- EPC $19.87
- DNTH $33.96
- Resistance Level
- EPC $21.05
- DNTH $40.16
- Average True Range (ATR)
- EPC 0.60
- DNTH 2.12
- MACD
- EPC 0.09
- DNTH -0.97
- Stochastic Oscillator
- EPC 54.44
- DNTH 4.03
About EPC Edgewell Personal Care Company
Edgewell Personal Care Co is a personal-care company. The operating segments of the company include Wet Shave, Sun and Skin Care and Feminine Care. Some of the brands offered by the company include Edge, Skintimate, Personna, Schick, Carefree, Playtex, Banana Boat and Hawaiian Tropic. It derives a majority of its revenue from the United States.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.